Biocon Biologics Germany GMBH

BALANCE SHEET AS AT MARCH 31, 2025

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Notes	March 31, 2025	March 31, 2024
ASSETS			
Non-current assets			
Property, plant and equipment		155	-
Total non-current assets		**155**	**-**
Current assets			
Inventories	1	8,679	-
Financial assets			
(i) Trade receivables	2	27,947	3,533
(ii) Cash and cash equivalents	3	10,657	759
Other current assets	4	268	2
Total current assets		**47,551**	**4,294**
TOTAL		**47,706**	**4,294**
EQUITY AND LIABILITIES			
Equity			
Equity share capital	5	25	25
Other equity	6	1,448	113
Total equity		**1,473**	**138**
Current liabilities			
Financial liabilities			
Trade payables	7	36,591	1,164
Income-tax liability (net)		590	48
Provisions	8	578	1,674
Other current liabilities	9	8,474	1,270
Total current liabilities		**46,233**	**4,156**
TOTAL		**47,706**	**4,294**

Biocon Biologics Germany GMBH

STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2025

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Notes	Year ended March 31, 2025	Year ended March 31, 2024
Income			
Revenue from operations	10	72,449	-
Other operating income	11	-	6,743
Total revenue		**72,449**	**6,743**
Expenses			
Purchases of traded goods	12	59,335	-
Changes in inventories of traded goods	13	(8,679)	-
Employee benefits expense	14	12,483	4,654
Other expenses	15	7,430	1,928
Total expenses		**70,569**	**6,582**
Profit before tax		**1,880**	**161**
Tax expense			
Current tax		545	48
Deferred Tax		-	-
Total tax expense		**545**	**48**
Profit for the year		**1,335**	**113**

Biocon Biologics Germany GMBH
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2025
(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2025	Year ended March 31, 2024
I Cash flows from operating activities		
Profit after tax	**1,335**	**113**
Adjustments to reconcile profit before tax to net cash flows:		
Unrealised foreign exchange loss	17	-
Tax expense	545	48
Operating profit before working capital changes	**1,897**	**161**
Movements in working capital		
(Increase)/Decrease in trade receivables	(24,431)	(3,533)
(Increase) in trade inventories	(8,679)	-
(Increase) in loans and advances and other assets	(266)	(2)
Increase in trade payable, other liabilities and provisions	41,534	4,108
Cash (utilised) / generated used in operations	**10,055**	**734**
Direct taxes paid	(3)	-
Net cash flow generated from operating activities	**10,052**	**734**
II Cash flows from investing activities		
Purchase of tangible assets	(155)	-
Net cash flow (utilised) in investing activities	**(155)**	**-**
III Cash flows from financing activities		
Proceeds from issue of equity shares	-	25
Net cash flow generated from financing activities	**-**	**25**
IV Net (decrease) / increase in cash and cash equivalents (I + II + III)	**9,897**	**759**
V Effect of exchange differences on cash and cash equivalents held in foreign currency	-	-
VI Cash and cash equivalents at the beginning of the period	759	-
VII Cash and cash equivalents at the end of the period (IV + V +VI)	**10,657**	**759**
Reconciliation of cash and cash equivalents as per statement of cash flow		
Cash and cash equivalents		
Balances with banks - on current accounts	10,657	759
Cash on hand		-
Total cash and cash equivalents [Refer note 3]	**10,657**	**759**

Biocon Biologics Germany GMBH
Notes to financial statements for the year ended March 31, 2025
(All amounts in EUR Thousands, except share data and unless otherwise stated)

	March 31, 2025	March 31, 2024
1. Inventories		
Finished Goods	8,679	-
	8,679	**-**
2. Trade receivables		
Other Receivables		
Outstanding for a period less than six months from the date they are due for payment		
Unsecured, considered good	27,947	3,533
	27,947	**3,533**
3. Cash and cash equivalents		
Balances with banks:		
On current accounts	10,657	759
	10,657	**759**
4. Other current assets		
Prepayments	268	2
	268	**2**
5. Share capital		
Authorised		
Issued, subscribed and fully paid-up		
Equity share 25,000 Common stock of EUR 1 each	25	25
	25	**25**
6. Other equity		
Surplus/(deficit) in the statement of profit and loss		
Balance as per the last financial statements	113	-
Profit / (Loss) for the period	1,335	113
Net surplus/(deficit) in the statement of profit and loss	**1,448**	**113**
Total other equity	**1,448**	**113**
7. Trade payables	**36,591**	**1,164**
8. Provisions		
Current		
Compensated absences	578	1,674
	578	**1,674**
9. Other liabilities		
Current liabilities		
Statutory liabilities	7,009	697
Employee related payables	1,465	573
	8,474	**1,270**

Biocon Biologics Germany GMBH
Notes to financial statements for the year ended March 31, 2025
(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2025	Year ended March 31, 2024
10. Revenue from operations		
Sale of Products		
Traded Goods	58,146	-
Sale of Services		
Support service cross charge to Group Companies	14,303	-
	72,449	**-**
11. Other operating income		
Support service cross charge to Group Companies	-	6,743
	-	**6,743**
12. Purchase of traded goods	59,335	-
	59,335	**-**
13. Changes in inventories of traded goods		
Inventory at the beginning of the year		
Traded goods	-	-
Inventory at the end of the year		
Traded goods	8,679	-
	(8,679)	**-**
14. Employee benefits expense		
Salaries, wages and bonus	12,248	4,616
Employee stock compensation expense	152	-
Staff welfare expenses	83	38
	12,483	**4,654**
15. Other expenses		
Rates and taxes	13	-
Rent	1,066	453
Legal and professional fees	2,096	352
Repair and Maintenance	470	32
Research and development expenses	7	-
Travelling and conveyance	566	427
Sales promotion expenses	2,031	478
Printing and stationery	176	114
Communication expenses	9	45
Miscellaneous expenses	180	28
Foreign exchange fluctuations, net	17	(1)
Distribution expenses	416	-
Insurance Charges	383	-
	7,430	**1,928**